Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial (GlobeNewswire) - Jun 22, 2022 - "Plus Therapeutics, Inc...and Biocept, Inc...announce a multi-year agreement to employ Biocept's cerebrospinal fluid (CSF) assay CNSide1 in Plus Therapeutics' ReSPECT-LM Phase 1/2a dose-escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM), which is cancer in the membranes that surround the brain and spinal cord."
Licensing / partnership • CNS Tumor • Oncology
|